# Estrogen in a rebound experiment

> Estrogen and the rebound | Menopause Consultants — Menopause Consultants examines endogenous estrogen in a growth-hormone rebound experiment involving 60 healthy postmenopausal women.

**The close examination**

The experiment becomes more interesting when estrogen is treated as an active participant.

## The postmenopausal experiment

[Veldhuis and colleagues studied 60 healthy postmenopausal women](https://pubmed.ncbi.nlm.nih.gov/27459535/). They depleted endogenous estrogen with anastrozole and examined the rebound growth-hormone secretion that followed a short intravenous somatostatin infusion. The rebound was mediated by GHRH; estrogen depletion markedly reduced it.

The authors' conclusion gives low levels of endogenous estrogen a role in hypothalamic-pituitary growth-hormone regulation. The hormonal background becomes a participant whose contribution can be tested. I appreciate the reversal: the background becomes an experimentally visible contribution. Reducing it changes the response.

The finding also alters the emphasis of a menopause discussion. The interesting observation here concerns the effect of estrogen that was present. I would reserve more of the discussion for that remaining influence before reaching for a story about adding another hormone.

![An illustrated technician prepares a clear laboratory assay plate on a pale workbench](images/assay-bench.webp)

*An imagined hormone-analysis bench accompanying the [postmenopausal rebound study](https://pubmed.ncbi.nlm.nih.gov/27459535/); the equipment is illustrative.*

## Following the rebound

The [study's measured outcome](https://pubmed.ncbi.nlm.nih.gov/27459535/) was a GHRH-mediated growth-hormone rebound after somatostatin. The sequence matters because it describes responsiveness following a controlled intervention, rather than a claim about everyday energy, sleep or symptom relief.

I see the experiment as a way of asking a system a specific question. What does the rebound depend on? In this setting, depleting endogenous estrogen blunted it. That is a more precise conclusion than declaring the entire growth-hormone system deficient or restored.

There is no tesamorelin outcome to credit to this experiment. Its contribution is physiological: a demonstration that low endogenous estrogen levels participated in regulation of the measured rebound.

> The result concerns a rebound response after an experimental infusion. Symptom relief would be a separate outcome.

## Experiments in men

In [26 healthy older men, secretagogue experiments involving GHRH, somatostatin and GHRP-2](https://pubmed.ncbi.nlm.nih.gov/23485864/) found that testosterone, estradiol and body mass index differentially controlled secretagogue-specific pulsatile growth-hormone secretion. Testosterone supplementation doubled GHRH-driven pulsatile output.

A separate [study in 24 young men with experimentally induced hypogonadism](https://pubmed.ncbi.nlm.nih.gov/19458139/) found that testosterone and estradiol depletion did not affect growth-hormone secretion stimulated by L-arginine plus GHRH or L-arginine plus GHRP-2. The population and experimental conditions were different.

The postmenopausal rebound experiment has a defined setting and a persuasive result within it. The men's experiments make the wider physiology more interesting, without supplying a substitute answer for those women.

## The next clinical question

A demonstration of hormonal influence opens a clinical question; it cannot choose a treatment on its own. A clinical study connecting the rebound response with a specified outcome in postmenopausal women would address the next clinical question. That is a question for future work, not a benefit measured in the rebound experiment.

[Tesamorelin](/tesamorelin) brings a modified GHRH analogue into the discussion. Its chemical design and its measured effects need their own examination.

---

At Menopause Consultants I examine what hormonal responses depend on in published research; this essay site is no consulting business, and its discussion provides no medical advice.